Clinical Study

Bpi-2358-103- Randomized Phase 3 Assessment Of Second Line Treatment With Docetaxel + Plinabulin Compared To Docetaxel Alone In Patients With Advanced Non-Small Cell Lung Cancer With At Least 1 Large Lung Lesion

Posted Date: Jun 17, 2019

  • Investigator: John Morris
  • Specialties: Cancer, Lung Cancer, Oncology
  • Type of Study: Drug

The goal of this study is to compare the overall survival of NSCLC patients receiving 2nd-or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease.


To Be Eligible: Must Have Nsclc, Age 18 Or Older, Lesion >10Mm, Life Expetancy >12 Weeks.


Lung Cancer, Nsclc, Phase Iii

For More Information:

Uc Cancer Institute

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.